Epsilon Healthcare Past Earnings Performance
Past criteria checks 0/6
Epsilon Healthcare's earnings have been declining at an average annual rate of -4.2%, while the Pharmaceuticals industry saw earnings declining at 0.8% annually. Revenues have been growing at an average rate of 16.1% per year.
Key information
-4.2%
Earnings growth rate
9.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 16.1% |
| Return on equity | -64.7% |
| Net Margin | -82.2% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Epsilon Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 7 | -6 | 5 | 0 |
| 31 Mar 23 | 7 | -10 | 6 | 0 |
| 31 Dec 22 | 7 | -13 | 6 | 0 |
| 30 Sep 22 | 6 | -13 | 7 | 0 |
| 30 Jun 22 | 5 | -13 | 7 | 0 |
| 31 Mar 22 | 5 | -11 | 8 | 0 |
| 31 Dec 21 | 5 | -9 | 10 | 0 |
| 30 Sep 21 | 6 | -9 | 11 | 0 |
| 30 Jun 21 | 7 | -9 | 12 | 0 |
| 31 Mar 21 | 7 | -10 | 11 | 0 |
| 31 Dec 20 | 7 | -11 | 11 | 0 |
| 30 Sep 20 | 7 | -11 | 11 | 0 |
| 30 Jun 20 | 6 | -12 | 11 | 0 |
| 31 Mar 20 | 5 | -12 | 10 | 0 |
| 31 Dec 19 | 5 | -12 | 10 | 0 |
| 30 Sep 19 | 4 | -11 | 9 | 0 |
| 30 Jun 19 | 4 | -11 | 9 | 0 |
| 31 Mar 19 | 3 | -10 | 9 | 0 |
| 31 Dec 18 | 3 | -9 | 8 | 0 |
| 30 Sep 18 | 3 | -7 | 7 | 0 |
| 30 Jun 18 | 3 | -5 | 6 | 0 |
| 31 Mar 18 | 2 | -4 | 5 | 0 |
| 31 Dec 17 | 2 | -3 | 3 | 0 |
Quality Earnings: HDRP.F is currently unprofitable.
Growing Profit Margin: HDRP.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HDRP.F is unprofitable, and losses have increased over the past 5 years at a rate of 4.2% per year.
Accelerating Growth: Unable to compare HDRP.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HDRP.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.7%).
Return on Equity
High ROE: HDRP.F has a negative Return on Equity (-64.69%), as it is currently unprofitable.